Episode 99: Early Mutation-Driver Positive NSCLC
In this episode, Josh and Michael examine the rapidly developing world of early lung cancer treatment. An area that will hopefully only grow in importance, treatment for early NSCLC is becoming ever more sophisticated, with recent developments in neoadjuvant management and confirmation of the benefit of adjuvant driver-mutation inhibitior treatment. Today's articles cover two such topics: will osimertinib finally reach the pinnacle it was born to reach and be used in the neoadjuvant treatment of EGFR-mutant NSCLC? Will alectinib join its older, more successful cousin in being effective in resected ALK-mutant NSCLC? Listen on to find out, but we'll give you this one for free: if you have a patient with early NSCLC, it is becoming imperative that you test them for these mutations. Truly a fascinating time.
Links to articles discussed in this episode (subscription may be required):
NEOS: https://www.lungcancerjournal.info/article/S0169-5002(23)00072-7/fulltext
